Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching from ETV to TDF in Japanese Chronic Hepatitis B
NCT03258710Phase 4Completed
- Sponsor
- GSK
- Start
- Oct 2017
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tenofovir disoproxil fumarate in Chronic Hepatitis B (CHB), sponsored by GSK. Primary endpoint: Percentage of Participants Who Achieved 0.25 Log10 HBsAg Reduction From the Baseline at Week 48. Started Oct 2017; status: completed.
02
Drugs
tenofovir disoproxil fumarate
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03258710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03258710.